Market Intelligence, Clinical Progress, and High-Purity Reagents for Muscarinic M2 Receptor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CHRM2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen Alternative | CHRM2 Full-length Sequence Verified Plasmid Optimized for transient transfection and expression verification. |
View CHRM2 Products |
| Gene Delivery | CHRM2 Promise-ORF / Lentivirus High-titer, sequence-verified lentiviral particles for stable cell line generation. Essential for native GPCR conformation. |
View CHRM2 Products |
| Benchmark Ab | Anti-CHRM2 Benchmark Antibody Recombinant positive control for surface expression validation. |
View CHRM2 Products |
| Validator | CHRM2 siRNA Set Target-specific knockdown pool for functional assay validation. |
View CHRM2 Products |
| Related Target A | CHRM1 Subfamily homolog. Crucial for counter-screening to prevent off-target cognitive side effects. |
View CHRM1 Products |
| Related Target B | CHRM3 Subfamily homolog. Essential for selectivity screening to avoid peripheral side effects (e.g., dry mouth, pupillary constriction). |
View CHRM3 Products |
| Related Target C | CHRM4 Subfamily homolog. Shares Gi/o coupling; required to verify subtype-specific therapeutic targeting. |
View CHRM4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of GPCRs | Lentivirus-mediated stable cell line construction preserves the 7-transmembrane native folding. |
| Subfamily Cross-reactivity & Selectivity | Complete CHRM family (CHRM1-5) lentivirus and plasmid panels available for parallel screening. |
| Lack of Controls | Sequence-verified clinical biosimilar antibodies included for assay benchmarking. |
| False Positives in Functional Assays | Validated siRNA sets included for target-specific knockdown verification. |
Live CHRM2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CHRM2 therapeutics is intensifying, with major players shifting focus from traditional non-selective muscarinic agonists to highly selective Allosteric Modulators (PAMs/NAMs) and subtype-specific biologics. As first-generation therapies for neurological and cardiovascular diseases reach the clinic, the next wave of R&D is targeting precise conformational states to minimize off-target cholinergic tox.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PAM/NAM) | Karuna Therapeutics (BMS), Cerevel Therapeutics (Pfizer) | Schizophrenia, Alzheimer's Psychosis | Selectivity Assay (Need CHRM1-5 Lentivirus Panel for stable cell lines) |
| Antibodies / Nanobodies | Sosei Heptares, Academic institutions | Cardiovascular diseases, Neuropathic Pain | Conformational validation (Need Lentivirus for high-expression cell lines) |
| RNA Therapeutics | Preclinical biotech developers | Autonomic Nervous System disorders | Knockdown efficiency verification (Need Sequence Verified siRNA & qPCR primers) |